Floatz logo

Nedaplatin

Advanced Solid Tumor

Wigen Biomedicine Technology (Shanghai) Co., Ltd.Small moleculePhase 2/3Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
59/ 100

Competitive context

1411 Active assets in the Advanced Solid Tumor cohort.

View all 50

Same molecule, other indications

Nedaplatin is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
Non-small Cell Lung CancerDormant
CCC
Indicative ·
54 / 100
View asset →
Hepatic Artery InfusionDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →